Author: therawinformant

What are the early trends we should look for to identify a stock that could multiply in value over the long term…

from Yahoo Finance https://ift.tt/2ATCocS

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

from Yahoo Finance https://ift.tt/2DEmioz

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

from Yahoo Finance https://ift.tt/3gOGZMT

Jul.13 — New York City Mayor Bill de Blasio led a group that painted a Black Lives Matter mural in bold yellow letters on 5th Avenue in front of Trump Tower on July 9. Similar murals have been painted on streets around the country.

from Yahoo Finance https://ift.tt/3eqguf8

Jul.13 — President Donald Trump issued a commutation for the prison sentence of Roger Stone late Friday. Stone was convicted of witness tampering and lying to Congress during the Russian election interference investigation. Stone is a political operative and long-time ally of Trump. Stone spoke to reporters in Florida on Saturday.

from Yahoo Finance https://ift.tt/2ZlJm3L

Shares in biotech Equillium (EQ) have almost tripled in Monday’s pre-market trading after the company announced that a clinical trial conducted in India by its partner Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19.Equillium is currently developing itolizumab to treat severe autoimmune and inflammatory disorders. The stock is currently trading up 260% in the pre-market.Biocon also announced that the Drugs Controller General of India (DCGI) has granted restricted emergency use of itolizumab for the treatment of cytokine release syndrome (CRS) in COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) in India.Based on the encouraging topline results and DCGI approval, Equillium revealed that it is now planning to conduct a global randomized controlled clinical trial of itolizumab in COVID-19 patients for which it will file a U.S. investigational new drug application (IND).Biocon conducted a randomized, controlled, open-label study at four hospitals in India, enrolling a total of 30 hospitalized COVID-19 patients with moderate to severe ARDS. Twenty patients were randomized to receive itolizumab plus best supportive care, while 10 patients received best supportive care alone. The primary endpoint was mortality at one month.As reported by Biocon: * In the itolizumab arm there were no deaths and all patients have recovered; in the control arm three patients died and the remainder have recovered * The mortality benefit observed in the itolizumab arm was statistically significant * Consistent with the observed clinical improvement, patients who received itolizumab also experienced significant reductions in inflammatory cytokines“The results of this clinical trial reported by Biocon are encouraging and support the hypothesis that itolizumab’s novel immune-modulating mechanism may have promise in addressing the severe immuno-inflammatory complications experienced by COVID-19 patients,” said Bruce Steel, CEO of Equillium.Itolizumab is a first-in-class immune-modulating antibody therapeutic with a novel mechanism of action that inhibits the activity and trafficking of pathogenic T cells that release pro-inflammatory cytokines in a range of autoimmune and inflammatory diseases. Equillium acquired rights to develop and commercialize itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.Equillium is currently evaluating itolizumab under two open U.S. INDs for the treatment of acute graft-versus-host disease and lupus nephritis, as well as conducting a clinical study in uncontrolled asthma in Australia and New Zealand.In March due to the emerging COVID-19 pandemic, Equillium announced that it was pausing enrollment in the EQUIP trial for uncontrolled asthma and the EQUALISE trial for lupus nephritis. Equillium has now announced that patient enrollment in both these studies has resumed.Two analysts have recently published buy ratings on EQ. That’s with an average price target of $12. Stifel Nicolaus analyst Derek Archila reiterated his buy rating on the stock following the latest news.“We note the trial in hospitalized COVID-19 patients was small (n=30), open-label and on top of standard of care, and little data were shared but according the Biocon/EQ press releases, the itolizumab arm did demonstrate a statistically significant benefit on mortality at one-month (the primary endpoint)” he told investors.The current literature suggests approximately ~8% of COVID-19 patients develop ARDS and if itolizumab were to be priced in line with Gilead’s (GILD) remdesivir (~$2,500-$3,000 per course) this could be a meaningful market opportunity for EQ, Archila added. (See EQ stock analysis on TipRanks).Related News: Australia Provisionally Approves Gilead’s Covid-19 Treatment Gilead Reveals Covid-19 Treatment Remdesivir Reduces Mortality Risk Moderna Inks Deal With Rovi To Supply Potential Covid-19 Vaccine Outside US More recent articles from Smarter Analyst: * Disney World Reopens To Small Numbers, Analyst Optimistic On Outlook * Alibaba Co-Founder Jack Ma Reduces Stake To 4.8% * South Korea: 1 in 3 Covid-19 Patients Improved With Gilead’s Remdesivir * Amgen Pours A Further $421M Into China’s BeiGene

from Yahoo Finance https://ift.tt/32fNR1E

The candidates, BNT162b1 and BNT162b2, are the most advanced of the at least four vaccines being assessed by the companies in ongoing trials in the United States and Germany. Pfizer’s shares were up about 2% and U.S.-listed shares of BioNTech were up about 6% before the bell. Earlier this month, the companies said BNT162b1 showed potential against the virus and was found to be well tolerated in early-stage human trials.

from Yahoo Finance https://ift.tt/3fqvbjo

Jensen Huang became the CEO of NVIDIA Corporation (NASDAQ:NVDA) in 1993, and we think it's a good time to look at the…

from Yahoo Finance https://ift.tt/3iXR3Fb

Walt Disney Co. (DIS) reopened its popular theme park, Disney World on July 10 after closing nearly four months ago as a result of the COVID-19 outbreak.The theme park reported attendance for its two areas, Magic Kingdom and Animal Kingdom with a combined 16,000 visitors for the reopening. This falls well below the pre-COVID average of nearly 100,000 people per day. Disney plans to reopen the remainder of its park on July 15.Disney’s stock was up 2% at market close on July 10 at $119.32 per share.Disney is requiring everyone in the park to wear a mask except for swimming as well as eating and drinking. A limited number of restaurants and hotels are back in business and more are planning to open in the coming months.J.P. Morgan analyst Alexia Quadrani was optimistic on July 10 regarding Disney World saying that the “reopening of the parks globally is a critical sign of recovery as this removes the largest overhang at the company due to Covid-19.” She also highlighted Disney’s streaming platform known as Disney+, saying with “increasing conviction that the health of the company is returning throughout several of its segments, with a move toward profitability in fiscal 2023 at Disney+, the reopening of the parks, and the return of live sports.” The analyst reiterated a Buy rating on the shares and a price target of $135 (implying 13% upside potential).In May, Disney revealed a loss of $1.4 billion in its second-quarter earnings. The amount accounts for its theme parks, retail stores, TV operations, and other divisions.Disney said on May 5, “The impact of COVID-19 and measures to prevent its spread is affecting our segments in a number of ways, most significantly at Parks, Experiences and Products where we have closed our theme parks and retail stores, suspended cruise ship sailings and guided tours and experienced supply chain disruptions.”The result of the pandemic mainly impacted its theme parks in Florida, California, Paris, Tokyo, and Shanghai in addition to Disney’s cruise ships. Overall Disney earnings fell to $475 million which was a 91% loss compared to $5.4 billion reported earnings in the same period last year.On July 8, Guggenheim analyst Michael Morris lowered his Q3 and Q4 estimates for Disney’s theme parks and media as a result of the Q2 earnings. He maintains a Hold rating on the stock and raised the price target from $115 to $123, which implies a 3% upside potential.Disney’s stock is down 18% year-to-date. Overall, 8 analysts assign Buy ratings, 11 Hold ratings, and 2 Sell ratings, giving Disney a Moderate Buy Street consensus. The average analyst price target stands at $122.18 suggesting 2% upside potential in the coming months. (See Disney's stock analysis on TipRanks).Related News: Disney: Uncertainty Keeps This 5-Star Analyst on the Sidelines Electronic Arts CEO Wants More Star Wars Games With Disney Disney’s Long Road to Recovery Moves This Analyst on the Sidelines More recent articles from Smarter Analyst: * Equillium Explodes 260% On Positive Covid-19 Results; India Approval * Alibaba Co-Founder Jack Ma Reduces Stake To 4.8% * South Korea: 1 in 3 Covid-19 Patients Improved With Gilead’s Remdesivir * Amgen Pours A Further $421M Into China’s BeiGene

from Yahoo Finance https://ift.tt/3j12Pyr

(Bloomberg) — Moderna Inc.’s experimental vaccine for Covid-19 could generate sales of more than $5 billion a year, Jefferies analyst Michael Yee said, initiating the stock at a buy.A 220% surge for the stock since the start of the year has split Wall Street as to “what will happen or if the vaccine will even work, and is hugely divided on valuation,” Yee wrote in a note to clients.“We believe the Street will be surprised to the upside if the Covid-19 vaccine works, gets approved by early 2021, and there are multi-billion dollars of purchase orders from USA and around the world,” he said.With a 30,000 person late-stage study set to kick off sometime this month, Moderna’s shot leads the pack in the race to get a vaccine to the world at large as the pandemic continues to spread.Yee predicts mRNA-1273, as the inoculation is known, will get “at least” an emergency use authorization by early next year. There are more than 20 candidates in human testing, while at least another 130 vaccines are in even earlier stages of development, according to the World Health Organization.The analyst assigns the biotechnology company a $90 price target, which is largely in-line with the $88 average price target of analysts tracked by Bloomberg. The Cambridge, Massachusetts-based company has 12 other buys and a single hold rating, while no analyst followed by Bloomberg currently rates it a sell.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/3gUoPcG